Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

16 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Corticosteroid Medication Week 38 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 38

- 14/07/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Week 38/ Early Withdrawal visit. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 32 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 32

- 12/07/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Week 32. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 28 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 28

- 12/07/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Week 28. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 24 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 24

- 12/07/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Week 24. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 20 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 20

- 12/07/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Week 20. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 16 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 16

- 12/07/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Week 16. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Weeks 9- 11 Mepolizumab HES NCT00086658 - Corticosteroid Medication Weeks 9- 11

- 10/07/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Weeks 9- 11. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 12 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 12

- 10/07/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Week 12. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 8 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 8

- 09/07/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Week 8. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Weeks 5 - 7 Mepolizumab HES NCT00086658 - Corticosteroid Medication Weeks 5 - 7

- 09/07/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Weeks 5 - 7. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 4 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 4

- 11/06/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Week 4. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Corticosteroid Medication Week 1-3 Mepolizumab HES NCT00086658 - Corticosteroid Medication Week 1-3

- 11/06/2017 - 1 Formulaire, 1 Groupe Item, 1 Élément de données, 1 Langue
Groupe Item: Corticosteroid Medication
Study part: Corticosteroid Medication Week 1-3. A Phase 2 Multicenter, Double-blind, Placebo-controlled, Study to to Evaluate the Corticosteroid- sparing effects of Mepolizumab in Subjects with Hypereosinophilic Syndromes (HES) and Evaluate Efficacy and Safety of Mepolizumab in Controlling the Clinical Signs and Symptoms of subjects with HES Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Sponsor: GlaxoSmithKline. Study ID: 100185, Clinical Study ID:MHE100185.

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial